MA29524B1 - Anticorps diriges contre la myostatine - Google Patents

Anticorps diriges contre la myostatine

Info

Publication number
MA29524B1
MA29524B1 MA30410A MA30410A MA29524B1 MA 29524 B1 MA29524 B1 MA 29524B1 MA 30410 A MA30410 A MA 30410A MA 30410 A MA30410 A MA 30410A MA 29524 B1 MA29524 B1 MA 29524B1
Authority
MA
Morocco
Prior art keywords
myostatin
antibodies
human antibodies
relates
directed against
Prior art date
Application number
MA30410A
Other languages
English (en)
Inventor
Eva Rose Chin
Chikwendu Ibebunjo
Philip Albert Krasney
Junming Yie
Joseph Zachwieja
Larry Green
Original Assignee
Pfizer
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Amgen Fremont Inc filed Critical Pfizer
Publication of MA29524B1 publication Critical patent/MA29524B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps parmi lesquels figurent des anticorps humains, et des parties de liaison à l'antigène correspondantes, qui se lient à la myostatine, et dont la fonction est d'inhiber la myostatine. L'invention concerne également des anticorps humains dirigés contre la myostatine, ainsi que des parties de liaison à l'antigène correspondantes. Cette invention se rapporte aussi à des anticorps qui sont chimériques, bispécifiques, dérivatisés, monocaténaires, ou qui se présentent sous la forme de parties de protéines de fusion. L'invention concerne par ailleurs des immunoglobulines isolées à chaîne lourde et à chaîne légère qui sont dérivées d'anticorps humains dirigés contre la myostatine, et des molécules codant ces immunoglobulines. L'invention concerne en outre des procédés pour produire des anticorps humains dirigés contre la myostatine, des compositions contenant des anticorps, et des procédés d'utilisation de ces anticorps et de ces compositions à des fins de diagnostic et de traitement. L'invention concerne également des procédés de thérapie génique faisant appel à des molécules d'acide nucléique codant les molécules d'immunoglobuline à chaîne lourde et/ou à chaîne légère qui comprennent les anticorps humains dirigés contre la myostatine. La présente invention concerne également des animaux ou des plantes transgéniques comprenant les molécules d'acide nucléique selon l'invention.
MA30410A 2005-04-25 2007-11-22 Anticorps diriges contre la myostatine MA29524B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67493305P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
MA29524B1 true MA29524B1 (fr) 2008-06-02

Family

ID=37215358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30410A MA29524B1 (fr) 2005-04-25 2007-11-22 Anticorps diriges contre la myostatine

Country Status (23)

Country Link
US (2) US7807159B2 (fr)
EP (2) EP1877075A4 (fr)
JP (1) JP2008539241A (fr)
KR (1) KR20080011403A (fr)
CN (1) CN101272802A (fr)
AP (1) AP2007004243A0 (fr)
AR (1) AR053067A1 (fr)
AU (1) AU2006239860B2 (fr)
BR (1) BRPI0610248A2 (fr)
CA (1) CA2605723A1 (fr)
CR (1) CR9466A (fr)
DO (1) DOP2006000093A (fr)
EA (2) EA015534B1 (fr)
IL (1) IL186739A (fr)
MA (1) MA29524B1 (fr)
MX (1) MX2007013217A (fr)
NL (3) NL1031674C2 (fr)
NO (1) NO20076061L (fr)
PE (1) PE20061395A1 (fr)
TN (1) TNSN07394A1 (fr)
TW (1) TW200724548A (fr)
WO (1) WO2006116269A2 (fr)
ZA (1) ZA200709291B (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP2781222B1 (fr) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Antagonistes de l'activine-actriia destinés à être utilisés pour la promotion de la croissance osseuse
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
PL2066695T3 (pl) * 2006-09-05 2013-08-30 Lilly Co Eli Przeciwciała przeciwko miostatynie
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
AU2012265564B2 (en) * 2006-09-08 2016-05-26 Amgen Inc Anti-activin A antibodies and uses thereof
TW200908982A (en) 2007-06-01 2009-03-01 Wyeth Corp Treatment of imatinib resistant leukemia
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
TW200911237A (en) 2007-08-03 2009-03-16 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
DK2245064T3 (da) * 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
EP2275443B1 (fr) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (fr) 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
WO2010080463A1 (fr) * 2008-12-18 2010-07-15 Imclone Llc Humanisation d'anticorps
AR074777A1 (es) * 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3332796A1 (fr) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Protéines actriib et variants et leurs utilisations se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2808382A1 (fr) * 2010-08-16 2012-02-23 Amgen Inc. Anticorps se liant a la myostatine, compositions et procedes
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013125667A1 (fr) 2012-02-24 2013-08-29 中外製薬株式会社 MOLÉCULE DE LIAISON D'ANTIGÈNE DESTINÉE À FAVORISER LA DISPARITION D'ANTIGÈNE VIA LE RÉCEPTEUR FcγRIIB
MY177331A (en) * 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
ES2791778T3 (es) 2012-08-01 2020-11-05 Ikaika Therapeutics Llc Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
SG10201912773TA (en) * 2012-08-23 2020-02-27 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
WO2014030750A1 (fr) 2012-08-24 2014-02-27 中外製薬株式会社 ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
HUE043482T2 (hu) 2012-09-13 2019-08-28 Bristol Myers Squibb Co Miosztatint megkötõ fibronektin alapú váz domén proteinek
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
CN103145836A (zh) * 2013-02-07 2013-06-12 浙江大学 抗肌抑素单链抗体及其编码基因、表达载体、重组转化子和应用
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
EP3007719B1 (fr) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Procédés et compositions pour augmenter la neurogenèse et l'angiogenèse
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CA2923145C (fr) 2013-09-05 2025-09-16 Amgen Inc. Molecules contenant des fc et presentant des profils de glycoforme previsibles, uniformes et reproductibles
EP3119418B1 (fr) * 2014-03-21 2022-02-23 Acceleron Pharma Inc. Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
TW201622746A (zh) * 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (fr) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
US9969807B2 (en) 2015-04-08 2018-05-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
WO2016168613A1 (fr) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6664129B2 (ja) * 2015-09-10 2020-03-13 学校法人慶應義塾 筋萎縮の予防剤及び／又は治療剤のスクリーニング方法
PT3922645T (pt) * 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
WO2017062835A2 (fr) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
EP3390443A4 (fr) 2015-12-18 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
WO2017110981A1 (fr) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
ES2893813T3 (es) 2016-01-06 2022-02-10 Harvard College El tratamiento con GDF11 previene el aumento de peso, mejora la tolerancia a la glucosa y reduce la hepatoesteatosis
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
KR20210082548A (ko) 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
MX2018014375A (es) 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y metodos de uso.
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
SI3555132T1 (sl) * 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
US11155611B2 (en) * 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
WO2020132647A1 (fr) 2018-12-21 2020-06-25 Northwestern University Utilisation d'annexines dans la prévention et le traitement d'une lésion de la membrane musculaire
WO2020139977A1 (fr) 2018-12-26 2020-07-02 Northwestern University Utilisation de stéroïdes de glucocorticoïdes dans la prévention et le traitement de l'atrophie musculaire, du vieillissement et du trouble métabolique
CN113874400B (zh) 2019-03-11 2025-02-07 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
CN111549031A (zh) * 2020-05-26 2020-08-18 上海海洋大学 一种草鱼和青鱼肌间刺变粗的分子育种方法
CN111549030A (zh) * 2020-05-26 2020-08-18 上海海洋大学 一种鲫鱼肌间刺变粗的分子育种方法
CN111560401A (zh) * 2020-05-26 2020-08-21 上海海洋大学 一种翘嘴红鲌和团头鲂肌间刺变粗的分子育种方法
CN111500581A (zh) * 2020-05-26 2020-08-07 上海海洋大学 一种鲢鱼和鳙鱼肌间刺变粗的分子育种方法
WO2021247892A1 (fr) 2020-06-04 2021-12-09 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022119367A1 (fr) * 2020-12-03 2022-06-09 ㈜라트바이오 Animal transgénique ayant un gène de myostatine modifié
CN117615787A (zh) * 2021-03-12 2024-02-27 西奈山伊坎医学院 针对bk病毒的中和单克隆抗体
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (fr) 2021-10-05 2023-04-13 Amgen Inc. Liaison de récepteur fc-gamma et teneur en glycane
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
CA3247001A1 (fr) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Anticorps contre le siglec-9 humain et leur utilisation pour l’immunothérapie
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법
CN115951044B (zh) * 2022-12-02 2025-02-18 北京世纪沃德生物科技有限公司 基于胶乳免疫比浊法测定s100a8/9的试剂盒及方法
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2026090253A1 (fr) 2024-10-23 2026-04-30 Amgen Inc. Procédés de détermination de la teneur en appariement de glycanes

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998052976A1 (fr) 1997-05-21 1998-11-26 Biovation Limited Procede de production de proteines non immunogenes
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2467597A1 (fr) * 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
JP5110877B2 (ja) * 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies

Also Published As

Publication number Publication date
TW200724548A (en) 2007-07-01
NL1031674C2 (nl) 2007-04-26
NL2002255C2 (nl) 2009-09-24
EA200702327A1 (ru) 2008-04-28
CR9466A (es) 2008-02-13
IL186739A0 (en) 2008-02-09
AP2007004243A0 (en) 2007-12-31
IL186739A (en) 2012-12-31
US7807159B2 (en) 2010-10-05
AR053067A1 (es) 2007-04-18
NL1033650A1 (nl) 2007-05-16
EP2295466A3 (fr) 2011-08-17
EA201100642A1 (ru) 2011-12-30
NL2002255A1 (nl) 2009-03-26
CA2605723A1 (fr) 2006-11-02
TNSN07394A1 (en) 2009-03-17
EP2295466A2 (fr) 2011-03-16
PE20061395A1 (es) 2007-01-15
WO2006116269A3 (fr) 2007-03-01
BRPI0610248A2 (pt) 2010-06-08
WO2006116269A2 (fr) 2006-11-02
US20060263354A1 (en) 2006-11-23
NL1031674A1 (nl) 2006-10-27
EP1877075A2 (fr) 2008-01-16
AU2006239860B2 (en) 2012-01-19
CN101272802A (zh) 2008-09-24
EP1877075A4 (fr) 2008-07-30
US20110091455A1 (en) 2011-04-21
KR20080011403A (ko) 2008-02-04
NL1033650C2 (nl) 2009-01-12
DOP2006000093A (es) 2007-01-31
JP2008539241A (ja) 2008-11-13
NO20076061L (no) 2007-11-26
ZA200709291B (en) 2009-01-28
EA015534B1 (ru) 2011-08-30
AU2006239860A1 (en) 2006-11-02
MX2007013217A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
WO2008019290A3 (fr) Anticorps anti-erbb2
MY140862A (en) ANTIBODIES TO MAdCAM
MA28092A1 (fr) Anticorps diriges contre un m-csf
TNSN07394A1 (en) Antibodies to myostatin
AP1918A (en) Antibodies to CD40
MA29991B1 (fr) Anticorps contre la p-cadherine
AP2072A (en) Antibodies to insulin-like growth factor I receptor
WO2008060331A3 (fr) Anticorps au coronavirus sras
AU2003220525A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
MA48241A1 (fr) Anticorps dirigés contre madcam
TNSN02089A1 (fr) Anticorps a cd40